vs
OPPENHEIMER HOLDINGS INC（OPY）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是OPPENHEIMER HOLDINGS INC的1.6倍（$772.1M vs $472.6M），OPPENHEIMER HOLDINGS INC净利率更高（15.7% vs 12.7%，领先3.0%），OPPENHEIMER HOLDINGS INC同比增速更快（25.9% vs 5.9%），OPPENHEIMER HOLDINGS INC自由现金流更多（$183.6M vs $161.8M），过去两年OPPENHEIMER HOLDINGS INC的营收复合增速更高（15.7% vs 9.0%）
奥本海默控股是一家美国跨国独立投资银行与金融服务企业，面向全球客户提供投资银行、财务咨询、资本市场、资产管理及财富管理等相关产品与服务，目前总部设于纽约市宽街85号。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
OPY vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.6倍
$472.6M
营收增速更快
OPY
高出20.0%
5.9%
净利率更高
OPY
高出3.0%
12.7%
自由现金流更多
OPY
多$21.8M
$161.8M
两年增速更快
OPY
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $472.6M | $772.1M |
| 净利润 | $74.4M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 22.4% | 14.5% |
| 净利率 | 15.7% | 12.7% |
| 营收同比 | 25.9% | 5.9% |
| 净利润同比 | 593.1% | 3.9% |
| 每股收益（稀释后） | $6.51 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPYRVTY
| Q4 25 | $472.6M | $772.1M | ||
| Q3 25 | $424.4M | $698.9M | ||
| Q2 25 | $373.2M | $720.3M | ||
| Q1 25 | $367.8M | $664.8M | ||
| Q4 24 | $375.4M | $729.4M | ||
| Q3 24 | $373.4M | $684.0M | ||
| Q2 24 | $330.6M | $691.7M | ||
| Q1 24 | $353.1M | $649.9M |
净利润OPYRVTY
| Q4 25 | $74.4M | $98.4M | ||
| Q3 25 | $21.7M | $46.7M | ||
| Q2 25 | $21.7M | $53.9M | ||
| Q1 25 | $30.7M | $42.2M | ||
| Q4 24 | $10.7M | $94.6M | ||
| Q3 24 | $24.5M | $94.4M | ||
| Q2 24 | $10.3M | $55.4M | ||
| Q1 24 | $26.1M | $26.0M |
毛利率OPYRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率OPYRVTY
| Q4 25 | 22.4% | 14.5% | ||
| Q3 25 | 7.5% | 11.7% | ||
| Q2 25 | 8.6% | 12.6% | ||
| Q1 25 | 11.2% | 10.9% | ||
| Q4 24 | 4.5% | 16.3% | ||
| Q3 24 | 9.5% | 14.3% | ||
| Q2 24 | 4.8% | 12.4% | ||
| Q1 24 | 10.6% | 6.8% |
净利率OPYRVTY
| Q4 25 | 15.7% | 12.7% | ||
| Q3 25 | 5.1% | 6.7% | ||
| Q2 25 | 5.8% | 7.5% | ||
| Q1 25 | 8.3% | 6.4% | ||
| Q4 24 | 2.9% | 13.0% | ||
| Q3 24 | 6.6% | 13.8% | ||
| Q2 24 | 3.1% | 8.0% | ||
| Q1 24 | 7.4% | 4.0% |
每股收益（稀释后）OPYRVTY
| Q4 25 | $6.51 | $0.86 | ||
| Q3 25 | $1.90 | $0.40 | ||
| Q2 25 | $1.91 | $0.46 | ||
| Q1 25 | $2.72 | $0.35 | ||
| Q4 24 | $0.92 | $0.77 | ||
| Q3 24 | $2.16 | $0.77 | ||
| Q2 24 | $0.92 | $0.45 | ||
| Q1 24 | $2.37 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $38.4M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $983.8M | $7.3B |
| 总资产 | $3.7B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OPYRVTY
| Q4 25 | $38.4M | $919.9M | ||
| Q3 25 | $38.3M | $931.4M | ||
| Q2 25 | $37.6M | $991.8M | ||
| Q1 25 | $36.7M | $1.1B | ||
| Q4 24 | $33.1M | $1.2B | ||
| Q3 24 | $32.2M | $1.2B | ||
| Q2 24 | $33.2M | $2.0B | ||
| Q1 24 | $27.7M | $1.7B |
总债务OPYRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $112.8M | — | ||
| Q2 24 | $112.8M | — | ||
| Q1 24 | $112.7M | — |
股东权益OPYRVTY
| Q4 25 | $983.8M | $7.3B | ||
| Q3 25 | $920.3M | $7.4B | ||
| Q2 25 | $896.9M | $7.6B | ||
| Q1 25 | $872.3M | $7.6B | ||
| Q4 24 | $850.4M | $7.7B | ||
| Q3 24 | $837.8M | $7.9B | ||
| Q2 24 | $812.1M | $7.9B | ||
| Q1 24 | $801.5M | $7.8B |
总资产OPYRVTY
| Q4 25 | $3.7B | $12.2B | ||
| Q3 25 | $3.8B | $12.1B | ||
| Q2 25 | $3.7B | $12.4B | ||
| Q1 25 | $3.6B | $12.4B | ||
| Q4 24 | $3.4B | $12.4B | ||
| Q3 24 | $3.4B | $12.8B | ||
| Q2 24 | $3.3B | $13.4B | ||
| Q1 24 | $3.3B | $13.4B |
负债/权益比OPYRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $188.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $183.6M | $161.8M |
| 自由现金流率自由现金流/营收 | 38.8% | 21.0% |
| 资本支出强度资本支出/营收 | 1.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.54× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $191.3M | $509.4M |
8季度趋势，按日历期对齐
经营现金流OPYRVTY
| Q4 25 | $188.8M | $182.0M | ||
| Q3 25 | $63.4M | $138.5M | ||
| Q2 25 | $40.1M | $134.3M | ||
| Q1 25 | $-91.7M | $128.2M | ||
| Q4 24 | $-108.2M | $174.2M | ||
| Q3 24 | $11.4M | $147.9M | ||
| Q2 24 | $-115.3M | $158.6M | ||
| Q1 24 | $-79.0M | $147.6M |
自由现金流OPYRVTY
| Q4 25 | $183.6M | $161.8M | ||
| Q3 25 | $62.2M | $120.0M | ||
| Q2 25 | $38.9M | $115.5M | ||
| Q1 25 | $-93.4M | $112.2M | ||
| Q4 24 | $-113.3M | $149.8M | ||
| Q3 24 | $11.2M | $125.6M | ||
| Q2 24 | $-116.7M | $136.6M | ||
| Q1 24 | $-79.3M | $129.7M |
自由现金流率OPYRVTY
| Q4 25 | 38.8% | 21.0% | ||
| Q3 25 | 14.7% | 17.2% | ||
| Q2 25 | 10.4% | 16.0% | ||
| Q1 25 | -25.4% | 16.9% | ||
| Q4 24 | -30.2% | 20.5% | ||
| Q3 24 | 3.0% | 18.4% | ||
| Q2 24 | -35.3% | 19.7% | ||
| Q1 24 | -22.5% | 20.0% |
资本支出强度OPYRVTY
| Q4 25 | 1.1% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 0.5% | 2.4% | ||
| Q4 24 | 1.4% | 3.4% | ||
| Q3 24 | 0.1% | 3.3% | ||
| Q2 24 | 0.4% | 3.2% | ||
| Q1 24 | 0.1% | 2.7% |
现金转化率OPYRVTY
| Q4 25 | 2.54× | 1.85× | ||
| Q3 25 | 2.92× | 2.97× | ||
| Q2 25 | 1.85× | 2.49× | ||
| Q1 25 | -2.99× | 3.03× | ||
| Q4 24 | -10.08× | 1.84× | ||
| Q3 24 | 0.47× | 1.57× | ||
| Q2 24 | -11.23× | 2.87× | ||
| Q1 24 | -3.03× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OPY
| Advisory Fees | $166.6M | 35% |
| Capital Markets Segment | $155.5M | 33% |
| Other | $57.2M | 12% |
| Commissions From Sales And Trading | $52.9M | 11% |
| Bank Deposit Sweep Income | $27.7M | 6% |
| Mutual Fund Income | $8.9M | 2% |
| Investment Banking Capital Markets | $3.3M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
